Cell processing instruments market seen reaching $10.1B by 2030

The Business Research Company says the cell processing instruments market will grow from $6.95 billion in 2025 to $7.51 billion in 2026, then reach $10.1 billion by 2030. The report points to biopharmaceutical investment, automation, and cell therapy demand as the main growth drivers, with North America leading in 2025 and Asia-Pacific expected to grow fastest.

Why it matters: - Cell processing instruments are becoming more important as biotech and biopharma teams need sterile, standardized cell handling for research and production. - The market’s growth tracks broader spending on cell therapy, regenerative medicine, and advanced lab automation. - The shift affects research labs, manufacturers, and contract development groups that rely on consistent cell analysis and processing.

What happened: - The Business Research Company released a report on the global cell processing instruments market on July 30, 2026. - The report estimates the market will rise from $6.95 billion in 2025 to $7.51 billion in 2026. - The report projects the market will reach $10.1 billion by 2030. - The 2026-2030 forecast implies a 7.7% compound annual growth rate. - North America held the largest regional share in 2025. - Asia-Pacific is projected to be the fastest-growing regional market.

The details: - Cell processing instruments are specialized tools used in controlled laboratory and manufacturing environments. - The instruments are designed to provide accurate, sterile, and consistent conditions for preparing cells under standardized protocols. - Historical growth reflects limited automation in cell processing workflows, manual cell counting and separation, academic and research activity, demand for precise cell analysis, and adoption of flow cytometry. - Future growth is tied to integrated cell processing platforms, funding for cell therapy and regenerative medicine, digital and automated imaging systems, contract research and manufacturing activity, and improvements in live cell analysis and high-content screening. - The report highlights a growing preference for automated cell processing systems, wider use of flow cytometry and high-content imaging, expansion of cell therapy applications, standardization and regulatory compliance, and multifunctional cell analysis platforms. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The Business Research Company offers a free sample of the report. - The Business Research Company also provides the full market report.

Between the lines: - Rising biopharmaceutical investment is the clearest demand signal in the report. - The report cites January 2025 data from the BioIndustry Association showing the UK biotech sector secured £3.5 billion in 2024 investment, up 94% from the prior year. - That spending trend suggests more funding for tools that can scale cell-based therapy research and manufacturing. - The emphasis on automation and digital imaging suggests buyers want faster workflows and more reproducible results.

What's next: - The market is expected to keep expanding through 2030 as cell therapy and regenerative medicine programs grow. - Automated and multifunctional platforms are likely to take a larger share of new installations. - Asia-Pacific’s faster growth points to more competition and investment in that region. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

The bottom line: - The cell processing instruments market is moving from a niche lab category toward a broader growth market shaped by biopharma funding, automation, and cell therapy demand.